Tyson Banbury (an independent analysis for consideration)

Becton, Dickinson & Co. Tyson Banbury (an independent analysis for consideration) 2009 Annual Report: http://media.corporate-ir.net/media_files/irol/64/64106/reports/AR09/ataglance_med.html

Agenda 1 Summary 2 Industry Overview 3 Company Overview 4 Competitors 5 SWOT Analysis 6 Valuation 7 Recommendation

Summary • Leading global medical technology company • Develops, manufactures, and sells medical devices, instrument systems and reagents • Founded in 1897 • Headquarters in Franklin Lakes, NJ • Employs over 29,000 associates in over 50 countries • Ticker: (NYSE:BDX) • Current Price: $81.43 (12/05/2010) 2009 Annual Report: http://media.corporate-ir.net/media_files/irol/64/64106/reports/AR09/description.html

Industry Overview Key Issues Medical Equipment and Supplies • Aging population has lead to increased levels of medical treatment and hospital admissions • Diabetes mellitus has reached epidemic status according to the US Center for Disease Control (CDC) • Accounts for more than $130 billion of healthcare spending in US annually • Market for diabetes diagnostic, monitoring, and treatment devices will increase rapidly • High crude oil and natural gas prices has driven up the cost of plastic resins used for the manufacture of many disposable medical supplies Source: 2010 OneSource Information Services, Inc., Becton Dickinson OneStop Report

Industry Overview Significant Trends • Consolidation – US medical equipment and supplies market favors large companies • Better able to negotiate with Group Purchasing Organizations (GPOs) • Can better afford high cost of product development including FDA approval process • Smaller companies often targeted by large firms looking to acquire new technologies • E-Procurement – Growth in internet sites featuring medical products and purchasing information has introduced price transparency • Increased purchasing power of healthcare institutions and GPOs • R&D Expenditure – Maintaining a healthy product pipeline is key to protecting market share and maintaining revenues • Many companies continue to increase R&D expenditures in an attempt to stay at the forefront of this industry Source: 2010 OneSource Information Services, Inc., Becton Dickinson OneStop Report

Company Overview Recent Performance • Significantly outperformed market over last 5 years • Held even with market during financial crisis http://finance.yahoo.com/echarts?s=BDX+Interactive#chart15:symbol=bdx;range=5y;compare=^gspc;indicator=sma(20,200)+volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined

Company Overview History • 1897: BD founded by Maxwell W. Becton and Fairleigh S. Dickinson as a medical device import company • 1904: First acquisition of Philadelphia Surgical Company enables BD to manufacture its own surgical instruments • 1950: Sale of first sterile disposable product to American Red Cross marks successful transition from reusable to disposable products • 1954: BD produces first completely disposable syringe for use in a field test of the Salk polio vaccine • 1962: BD goes public, offering stock at $25/share • 1973: BD produces first fluorescence-activated cell-sorting system • 1999: Goal of becoming as universally recognized as the Red Cross http://www.bd.com/aboutbd/history/

Company Overview Segments – BD Medical Focus: Products that reduce spread of infection and enhance diabetes treatment, drug delivery, and ophthalmic surgery • Insulin syringes and pens • Needles and syringes • Intravenous catheters • Safety-engineered and auto disable devices • Prefillable drug delivery systems • Surgical blades and scalpels • Ophthalmic surgical instruments (FY 2009) 2009 Annual Report: http://media.corporate-ir.net/media_files/irol/64/64106/reports/AR09/ataglance_med.html

Company Overview Segments – BD Diagnostics Focus: Products that improve the accuracy and efficiency of diagnosis • Blood collection systems • Automated blood culturing systems • Molecular testing systems for STDs • Microorganism identification systems • Rapid diagnostic assays • Plated media (FY 2009) 2009 Annual Report: http://media.corporate-ir.net/media_files/irol/64/64106/reports/AR09/ataglance_diag.html

Company Overview Segments – BD Biosciences Focus: Products that help with cellular analysis and growing living cells and tissues • Fluorescence-activated cell sorters • Monoclonal antibodies • Reagent systems • Cell imaging systems • Cell culture media • Tissue culture supplies (FY 2009) 2009 Annual Report: http://media.corporate-ir.net/media_files/irol/64/64106/reports/AR09/ataglance_bio.html

Company Overview Segment Performance Data Source: 2010 and 2007 10-K’s, Notes to Financial Statements (Segment Data), pages 72 and 21-22 respectively

Company Overview Segment Performance • Maintained positive revenue growth in all segments despite financial crisis • Segment revenues maintain stable proportion of total revenues • Stable growth in BD Medical and BD Diagnostics consistent with industry drivers of aging US population and continued growth of diabetes epidemic • High growth in BD Biosciences reflects growing emphasis on biotechnology as the market recognizes the applicability of these medical technologies Source: 2010 OneSource Information Services, Inc., Becton Dickinson OneStop Report

Company Overview Financial Strength 1 Based on 5 year average Source: 2010 OneSource Information Services, Inc., Becton Dickinson OneStop Report

Company Overview Management • Ongoing investment in growth opportunities • Operational initiative to reduce costs of medical surgical products about 20% to 30% • Define functional transformation strategies to continue leveraging G&A cost structure, reducing costs going forward • Focus on productivity improvements • Continue expense management BD Q1 FY 2010 Conference Call: http://seekingalpha.com/article/185207-becton-dickinson-and-company-f1q10-earnings-conference-call

Competitors Baxter International, Inc. • Develops, manufactures, and markets products that save and sustain lives of people with hemophilia, immune disorders, infectious diseases, and other chronic and acute medical conditions. • Baxter manufactures products in 27 countries and sells them in more than 100 countries • Three business segments: • BioScience • Medication Delivery • Renal • Generates 60% of revenues outside US • FY 2010: Q1-Q3 Revenues up 3% but Net Income down 39% due to increased cost of sales, marketing expenses, and declining margins Source: 2010 OneSource Information Services, Inc., Baxter International, Inc. Company Summary

Competitors Stryker Corporation • Medical technology company focusing on orthopaedics among other medical specialty areas • Two business segments: • Orthopaedic Implants • MedSurg Equipment • Orthopaedic Implants: Hip, knee, and spinal implant systems • MedSurg Equipment: Surgical equipment, communications systems, patient handling, and emergency medical equipment • In 2010, multiple acquisitions including Porex Surgical and Neurovascular division of Boston Scientific • FY 2010: Q1-Q3 Revenues up 9%, Net Income up 22% due to increased gross profit and decreased SG&A expenses Source: 2010 OneSource Information Services, Inc., Stryker Corporation Company Summary

Competitors Zimmer Holdings, Inc. • Designs, develops, manufactures, and markets orthopaedic reconstructive implants, dental implants, spinal implants, and related surgical products • Operations in more than 25 countries and markets products in more than 100 countries • Three geographic segments: • Americas • Europe • Asia Pacific • FY 2010: Q1-Q3 Revenues up 3%, Net Income down <1% due to increased sales in Asia Pacific offset by higher SG&A, R&D and cost of production expenses Source: 2010 OneSource Information Services, Inc., Zimmer Holdings, Inc. Company Summary

Competitors Relative Performance http://finance.yahoo.com/echarts?s=BDX+Interactive#chart1:symbol=bdx;range=5y;compare=bax+syk+zmh;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined

SWOT Analysis Summary Source: 2010 OneSource Information Services, Inc., Becton Dickinson OneStop Report

SWOT Analysis Strengths • Financial Strength – Continued growth in sales, total assets, and current assets despite financial crisis • Strong cash & equivalents position: $830.5 million in 2008 to $1,216.0 million in 2010 • This increase in cash is driven by cash from operations • Focused R&D – R&D activities conducted at operating units and at BD Technologies located in Research Triangle Park, North Carolina • Heavy investment in R&D to maintain innovation (greater than 5% of Total Revenues annually) • In addition to in-house R&D, BD collaborates with universities and medical centers to stay at cutting edge of technologies • High investment on product development allows BD to deliver new technologies early to the market, allowing it to gain significant market share • Global Presence – International operations organized into Europe (including Middle East and Africa), Japan, Asia Pacific, Latin America, and Canada • Diverse geography of manufacturing sites (16 countries) shields BD from macroeconomic risks associated with have production concentrated in a single area • Diverse customer base includes healthcare institutions, clinical laboratories, life science researchers, the general public, and the pharmaceutical industry worldwide • 2009 Revenues: 44.8% from US, 34.6% from Europe, and 20.6% from other countries • Diverse Product Portfolio – Diverse set of products create segment revenues that are stable with strong future growth potential Source: 2010 OneSource Information Services, Inc., Becton Dickinson OneStop Report

SWOT Analysis Weaknesses • Product Recalls – On February 8, 2010, BD voluntarily recalled some lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems • Recall initiated because devices may cause air embolism, leakage of blood, injury or death • Such recalls have the potential to impact BD’s reputation as well as projected sales and profits • FDA Warning Letter – The US Food and Drug Administration (FDA) issued a warning letter to BD identifying that BD sells products intended to diagnose, prevent, and treat the 2009 H1N1 Flu Virus that have not been approved for this treatment. • Such letters have the potential to negatively impact BD’s image and possibly its operations • Pending Lawsuits – BD is a defendant in several pending lawsuits, a majority of which involve direct and indirect purchasers of its products • Antitrust violations • Patent infringement • These lawsuits may negatively impact BD’s brand and image Source: 2010 OneSource Information Services, Inc., Becton Dickinson OneStop Report

SWOT Analysis Opportunities • Growing Diabetes Care Device Market – The frequency of diabetes among children and adults is increasing worldwide and is the 6th leading cause of death in the US • Global market for diabetes care devices: $5,432.4 million in 2000 to $12,201.9 million in 2009 (CAGR = 9.4%). This market is projected to grow to $21,777.0 in 2016 (CAGR = 8.6%) • Growing incidence of diabetes provides new avenue of revenue growth; however, market penetration of diabetes care devices is as low as 1% in emerging economies, 30% in Western Europe, and 35% in the US. This low penetration rate provides opportunities for future growth. • Agreements and Collaborations – BD has recently entered into strategic collaborations with ReaMetrix, The US President’s Emergency Plan for AIDS Relief, and Luminex Corporation • These first two of these projects focus on improving technologies for diagnosis and treatment of the AIDS virus as well as expanding BD’s reach into resource-limited settings such as Africa • Strategic Acquisitions – Acquisition of smaller companies has been one of the main growth strategies of BD in the past, and will continue in the future • Acquisitions will help bring in new technologies and allow BD to meet the demands of growing customer requirements • Global Expansion - Building new manufacturing facilities in Hungary, China, and Canada will continue to diversify BD across international markets • Market Growth in Emerging Economies – Medical equipment market in China, India, and Brazil has grown at a CAGR of 6.5% over the last 8 years and is projected to grow at a CAGR of 7.3% until 2015 • Growth due to increased income levels and awareness of medical conditions Source: 2010 OneSource Information Services, Inc., Becton Dickinson OneStop Report

SWOT Analysis Threats • Extensive Government Regulation – Subject to local, state, federal, and foreign laws and regulations • Regulatory bodies include the FDA, Drug Enforcement Agency (DEA), National Research Council (NRC), Department of Health and Human Services (DHHS), and other comparable agencies across the world • Regulation will likely increase in the US as the financial crisis eventually passes and individuals’ focus returns to the recently passed healthcare bill and the general state of healthcare in the US • Competitive Environment – BD operates in a highly competitive industry where technology changes rapidly along with customer expectations • Recent improvements in transparency have given customers more pricing power • Entry by manufacturers based exclusively in China and other low-cost manufacturing locations continues to put pricing pressure on BD and may inhibit BD’s ability to capture market share in emerging markets • Government Funding – Many customers depend on grants from US government agencies, such as the National Institute of Health (NIH), for projects that require the purchase of BD’s products. • These availability of these funds fluctuates, making the future demand for BD’s products uncertain • Industry Consolidation Challenges – Consolidation in the medical device industry is leading to intense competition with larger companies better able to negotiate price concessions with buyers • May force BD to lower prices to maintain competitive stance, decreasing revenues Source: 2010 OneSource Information Services, Inc., Becton Dickinson OneStop Report

Valuation Drivers & Discount Rate • CAPM yielded ~7% cost of equity • This value was not used in this analysis

Valuation Market Multiples Analysis • Market Multiples Valuation two ways: • DCF with terminal value determined by industry market multiples • Traditional comparable companies analysis

Valuation Market Multiples Analysis – Implied Growth • BD trades dead on the average multiples for the industry  Industry is trading at an excessive premium due to high growth prospects • Terminal value determined by industry market multiples yields implied long-term growth rate of 6.60% • This long-term growth rate is unreasonably high, even given BD’s history of consistent high growth http://finance.yahoo.com/echarts?s=BDX+Interactive#chart14:symbol=bdx;range=my;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined

Valuation Discounted Cash Flow – Moderate LT Growth • DCF with a more reasonable long-term growth rate of 3.5% yields the following per share price range:

Recommendation • Current Price: $81.43 (12/05/2010) • Average price using market multiples: $81.37 • Price using moderate LT growth rate: $62.98 Recommend: • Add BD to the watch list • Monitor for opportunities to purchase at ~20% discount to current price due to market fluctuations or investor fears • Explore small and mid-cap firms in medical equipment and supplies industry that escape high analyst coverage and have high potential to be targeted by larger firms

Tyson Banbury (an independent analysis for consideration)